



ASX Announcement

For immediate release

23 April 2015

GORDON NAYLOR TO LEAD CSL'S GLOBAL INFLUENZA VACCINE BUSINESS

CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL's new global influenza vaccine business, which is planned for launch at the start of 2016. Mr Naylor is currently the Company's Chief Financial Officer and has held executive management responsibility for CSL's existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012.

In October 2014, CSL agreed to acquire Novartis' global influenza vaccine business for US\$275 million, and foreshadowed intentions to combine it with bioCSL. Completion of the acquisition is planned for 31 December 2015 and remains subject to regulatory approvals in a number of jurisdictions.

The combination of the two businesses is expected to create the world's second largest influenza vaccine manufacturing company with plants in the US, UK, Germany and Australia, a diversified product portfolio and strong pandemic capabilities in its major centres of operation. The business will continue to manufacture, in-license and distribute a broad range of vaccines and specialty pharmaceuticals in Australia and New Zealand.

"Gordon is a proven leader with the experience to integrate two strong vaccine companies and build a highly focused, growth-orientated global business," said CSL's Chief Executive Officer and Managing Director, Paul Perreault.

Since joining CSL in 1987, Mr Naylor has held a number of global operations and general management positions; serving as the Company's Chief Financial Officer since 2010. He has played important leadership roles in CSL's internationalisation, most notably in the successive integration of CSL Plasma and Aventis Behring. Mr Naylor then led the transformation of CSL Plasma, creating the globally integrated, low-cost supply chain that underpins CSL's operations today.

"Gordon's extensive experience positions him well to lead the new organisation," Mr Perreault said.

Mr Naylor will continue in his current role throughout a transition period with his successor. bioCSL's operations will continue under the management of the current leadership team until completion of the acquisition of the Novartis influenza vaccine business. An international search will shortly commence for Mr Naylor's successor as Chief Financial Officer, allowing for a planned transition process.



ASX Announcement

Page 2

23 April 2015

For further information, please contact:

Investors:

Mark Dehring
Head of Investor Relations
CSL Limited
Telephone: +613 9389 3407
Email: mark.dehring@csl.com.au

Media:

Sharon McHale
Senior Director Public Affairs
CSL Limited
Telephone: +613 9389 3425
Mobile +614 0997 8314
Email: sharon.mchale@csl.com.au